Table 1 Model input parameters

Mean age of patients

69

NA

NA

Not varied

[27]

Sex of patients (men)

59%

NA

NA

Not varied

[26]

Model cycle length

1 month

NA

NA

Not varied

[11, 28, 29]

Model time horizon

10 years

NA

NA

Not varied

[29]

Probability of AE (adjusted per cycle)

 DRd

0.011

0.009

0.0126

Beta

 KRd

0.026

0.0221

0.0299

Beta

Cost($)

 Specialist visit

2.08

1.66

2.5

Gamma

Tariff of IranianHS^a

 Labratory tests

20

16

24

Gamma

Tariff of IranianHS

 MRI

10.4

8.33

12.5

Gamma

Tariff of IranianHS

 CT

11.8

9.4

14.4

Gamma

Tariff of IranianHS

 Daratumumab 400 mg

274.2

219.4

329

Gamma

Iranian Food and Drug org

 Carfilzomib 60 mg

217

173

260

Gamma

irc.fda.gov.ir/nfi

 Dexamethasone 40 mg

0.83

0.66

1

Gamma

irc.fda.gov.ir/nfi

 Radiotherapy

14.2

11.4

17

Gamma

Tariff of IranianHS

 Lenalidolidomide 25 mg

2.9

2.3

3.5

Gamma

irc.fda.gov.ir/nfi

 Drug administration

19.7

15.8

23.6

Gamma

Tariff of IranianHS

 Management toxicity

21.6

16.4

25.1

Gamma

Tariff of IranianHS

 AE

24.4

19.5

29.2

Gamma

Tariff of IranianHS

Utility

 U_PFS

0.73

0.584

0.876

Betta

[29]

 Disutility_AE

− 0.049

− 0.0392

− 0.0588

Betta

[29]

 Disutility_Progression

− 0.054

− 0.0432

− 0.0648

Betta

[29]

Discount rate

 Cost

0.072

NA

NA

Not varied

[30]

 QALY

0.03

NA

NA

Not varied